These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24236473)

  • 1. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
    Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
    J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
    Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
    Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.
    Markovic-Pekovic V; Skrbić R; Godman B; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):661-71. PubMed ID: 23186404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.
    Godman B; Bucsics A; Burkhardt T; Schmitzer M; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):199-207. PubMed ID: 20384566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future.
    Vončina L; Strizrep T; Godman B; Bennie M; Bishop I; Campbell S; Vlahović-Palčevski V; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):469-79. PubMed ID: 21831028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
    Hesse U; Godman B; Petzold M; Martin A; Malmström RE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.
    Coma A; Zara C; Godman B; Agustí A; Diogène E; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):569-81. PubMed ID: 19941434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.
    Bucsics A; Godman B; Burkhardt T; Schmitzer M; Malmström RE
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):809-19. PubMed ID: 23252361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.
    Woerkom Mv; Piepenbrink H; Godman B; Metz Jd; Campbell S; Bennie M; Eimers M; Gustafsson LL
    J Comp Eff Res; 2012 Nov; 1(6):527-38. PubMed ID: 24236472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
    Fraeyman J; Van Hal G; Godman B; Beutels P
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):141-51. PubMed ID: 23402454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?
    Bennie M; Bishop I; Godman B; Campbell S; Miranda J; Finlayson AE; Gustafsson LL
    Qual Prim Care; 2013; 21(1):7-15. PubMed ID: 23735629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
    Bennie M; Godman B; Bishop I; Campbell S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the utilization of venlafaxine after the introduction of generics in Sweden.
    Godman B; Persson M; Miranda J; Skiöld P; Wettermark B; Barbui C; Gustafsson LL
    Appl Health Econ Health Policy; 2013 Aug; 11(4):383-93. PubMed ID: 23754677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.
    Huang SH; Hsu CN; Yu SH; Cham TM
    BMC Public Health; 2012 May; 12():288. PubMed ID: 22521158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
    Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
    Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
    Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmström RE; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):115-24. PubMed ID: 22280201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of prescription antihypertensive drug utilization and adherence to treatment guidelines in the city of Novi Sad.
    Tomas A; Tomić Z; Milijasević B; Ban M; Horvat O; Vukmirović S; Sabo A
    Vojnosanit Pregl; 2016 Jun; 73(6):531-7. PubMed ID: 27498444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period.
    Almadfaa RO; Wigle PR; Hincapie AL; Guo JJ
    Int J Cardiol; 2023 Jan; 370():412-418. PubMed ID: 36306953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
    McGinn D; Godman B; Lonsdale J; Way R; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):73-85. PubMed ID: 20121565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.